Matthew Ros

2019

In 2019, Matthew Ros earned a total compensation of $2.1M as Chief Strategy and Business Officer at Epizyme, a 21% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$199,861
Option Awards$899,137
Salary$432,600
Stock Awards$538,793
Other$11,598
Total$2,081,989

Ros received $899.1K in option awards, accounting for 43% of the total pay in 2019.

Ros also received $199.9K in non-equity incentive plan, $432.6K in salary, $538.8K in stock awards and $11.6K in other compensation.

Rankings

In 2019, Matthew Ros' compensation ranked 5,724th out of 13,971 executives tracked by ExecPay. In other words, Ros earned more than 59.0% of executives.

ClassificationRankingPercentile
All
5,724
out of 13,971
59th
Division
Manufacturing
2,143
out of 5,695
62nd
Major group
Chemicals And Allied Products
772
out of 2,194
65th
Industry group
Drugs
649
out of 1,880
66th
Industry
Pharmaceutical Preparations
476
out of 1,392
66th

Pay ratio

Matthew Ros' Pay$2,081,989
Median Employee's Pay$302,723
Pay Ratio

7

to 1

In 2019, the annual total compensation of Matthew Ros was $2,081,989.

The annual total compensation of the median employee at Epizyme was $302,723.

The ratio of Matthew Ros' pay to the pay of median employee was therefore 7 to one.

Source: SEC filing on April 17, 2020.

Ros' colleagues

We found four more compensation records of executives who worked with Matthew Ros at Epizyme in 2019.

2019

Robert Bazemore

Epizyme

Chief Executive Officer

2019

Shefali Agarwal

Epizyme

Chief Medical Officer

2019

Paolo Tombesi

Epizyme

Chief Financial Officer

2019

Suzanne Fleming

Epizyme

Former Senior Vice President, Finance and Treasurer

News

You may also like